Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin), returned positive top-line results.
Bio-Thera Solutions announced that a phase 3 clinical trial comparing the efficacy and safety of its bevacizumab biosimilar, BAT1706, to the reference product (Avastin) returned positive top-line results.
The Chinese commercial-stage biopharmaceutical company said in a press release that BAT1706 proved equivalent to bevacizumab in overall response rate as a first-line treatment for non-squamous non-small cell lung cancer.
“We are pleased to report on our second proposed biosimilar with positive study results,” said Shenfeng Li, PhD, the chief executive officer of Bio-Thera Solutions. “These results demonstrate the potential of our proposed bevacizumab biosimilar to be a safe and effective treatment option for cancer patients. Bio-Thera is committed to increasing patient access to innovative medicines through the development of high-quality biosimilars.”
Avastin is indicated in the US to treat metastatic colorectal cancer, non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer, along with other conditions.
According to the press release, “BAT1706 works by binding the vascular endothelial growth factor (VEGF) protein.” It has not yet received regulatory approval in any country.
The trial consisted of a multicenter, randomized, double-blind study which evaluated the pharmacokinetics and immunogenicity of BAT1706. Results of the study have yet to be released and the company is developing several other proposed biosimilars including ustekinumab, secukinumab and golimumab.
Separately this week, the FDA requested data for Formycon’s Lucentis biosimilar candidate FYB201, as part of a review process for a biologics license application (BLA). The company stated it will take around 4 months to generate the additional data. However, Bioeq, its licensing partner, announced it would withdraw its BLA for the biosimilar candidate, provide requested data, and resubmit the application after, which may delay approval of the BLA.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars
October 12th 2024A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.